Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: from birth to adulthood.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing pathophysiology, genetics, and clinical management without systematic review methodology.
PubMed 23044877 · doi:10.1055/s-0032-1324724
What was done
This is a narrative review examining congenital adrenal hyperplasia (CAH) caused by steroid 21-hydroxylase deficiency, covering underlying genetics (CYP21A2 gene mutations), clinical manifestations, newborn screening, lifelong glucocorticoid and mineralocorticoid replacement therapy, and the transition from pediatric to adult medical care.
What was found
The review notes that 21-hydroxylase deficiency accounts for >90% of CAH cases, with approximately 75% of classic severe cases exhibiting salt wasting due to aldosterone deficiency. It highlights that newborn screening reduces diagnostic delays and mortality from adrenal crises. Classic CAH requires chronic glucocorticoid treatment at the lowest effective dose alongside mineralocorticoid (fludrocortisone) therapy. No empirical outcome statistics or comparative trial data were reported in the abstract.
Why it matters
It outlines standard diagnostic and therapeutic strategies across the lifespan for the most common form of CAH, emphasizing prevention of adrenal crises and structured transition into adult endocrinology care.
Limits
As a narrative review, it lacks systematic search methodology, meta-analytic pooling, and risk-of-bias assessment. No original experimental data or quantitative comparative treatment outcomes are provided.
Cited by
- supports In congenital adrenal hyperplasia (CAH), impaired synthesis of adrenal steroids causes the pituitary to overstimulate the adrenal glands, leading to hypertrophy and excess production of testosterone and other androgens.